Rivaroxaban (Xarelto), a synthetically derived drug from Janssen Pharmaceuticals and Bayer Healthcare, inhibits the blood coagulation cascade by its inhibitory action on coagulation factor Xa, resulting in inhibition of fibrin clot formation.2
The STA-Rivaroxaban Calibrator (catalog # 00704US) and Control (catalog # 00706US) products contain two levels of control at the low and high end of the calibrator range. Both the calibrator and control are stable for 8 hours on board the STA-R Evolution Expert Series and STA Compact® automated coagulation analyzers. Utilization of STA-Rivaroxaban Calibrator and Controls ensures high specificity and precision for rivaroxaban determination. In addition, barcoding of critical information on the reagent vials prevents transcription errors.
The rivaroxaban controls and calibrators are labeled for research use only, and are not for use in diagnostic procedures in the United States and Canada.
- Harenberg et al. Semin Thromb Hemost 2012; 38: 178-184
- Samama, Thromb Res 2011; 127: 497-504
About Diagnostica Stago, Inc.
Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis. Diagnostica Stago, Inc. is the U.S. subsidiary of Diagnostica Stago, S.A.S. France, a leader in the development and manufacture of Hemostasis products. For more information about any Stago product or service, please call 800-222-COAG or visit our website at www.stago-us.com.
XARELTO is a registered trademark of Janssen Pharmaceuticals, Inc.
paul.riley@stago-us.com